JNCE - Jounce Therapeutics, Inc.
| Previous Close | 5.61 |
| Open | 5.55 |
| Bid | 0.00 x 800 |
| Ask | 8.50 x 1800 |
| Day's Range | 5.38 - 5.62 |
| 52 Week Range | 2.66 - 22.44 |
| Volume | 135,768 |
| Avg. Volume | 227,501 |
| Market Cap | 183.656M |
| Beta (3Y Monthly) | 3.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.84 |
| Earnings Date | Aug 9, 2018 - Aug 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.50 |
- Motley Fool•12 days ago
Here's Why Jounce Therapeutics Rose 39.3% in March
The biopharma announced full-year 2018 operating results.
- GlobeNewswire•19 days ago
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting
CAMBRIDGE, Mass., April 03, 2019 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies.
- GlobeNewswire•20 days ago
Jounce Therapeutics Reports Improved PFS and OS Associated with Vopratelimab (JTX-2011) Treatment Emergent Biomarker at the 2019 American Association for Cancer Research (AACR) Annual Meeting
Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported new clinical data on vopratelimab (JTX-2011) at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, GA. The Jounce poster presentations show that patients in the ICONIC trial with emergence of ICOS hi CD4 T cells have improved progression free survival (PFS) and overall survival (OS) compared to patients with ICOS lo CD4 T cells.
- Simply Wall St.•last month
Investors Who Bought Jounce Therapeutics (NASDAQ:JNCE) Shares A Year Ago Are Now Down 80%
It is doubtless a positive to see that the Jounce Therapeutics, Inc. (NASDAQ:JNCE) share price has gained some 47% in the last three months. But that is meagre solace whenRead More...
- Thomson Reuters StreetEvents•last month
Edited Transcript of JNCE.O earnings conference call or presentation 6-Mar-19 1:00pm GMT
Q4 2018 Jounce Therapeutics Inc Earnings Call
- GlobeNewswire•2 months ago
Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today reported financial results and provided a corporate update for the fourth quarter and year ended December 31, 2018. “In 2019, we plan to advance our first-in-class highly selective antibody JTX-8064, which targets the LILRB2 receptor on macrophages, by filing an IND and initiating a Phase 1 trial, supporting our goal of three immunotherapies in the clinic this year, while we continue to progress novel discovery programs toward development.
- GlobeNewswire•2 months ago
Jounce Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference
CAMBRIDGE, Mass., March 04, 2019 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies.
- GlobeNewswire•2 months ago
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Wednesday, March 6, 2019
CAMBRIDGE, Mass., Feb. 28, 2019 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies.
- GlobeNewswire•2 months ago
Jounce Therapeutics to Present Data from its JTX-2011 and JTX-8064 Programs at the 2019 American Association for Cancer Research (AACR) Annual Meeting
ICONIC Clinical Data Demonstrates Improved PFS/OS in Patients with Emergence of JTX-2011 Mechanistic Biomarker (ICOS high CD4 T cells) Company to Host Investor Event and Live.
- American City Business Journals•3 months ago
In-house lawyers demand diversity, but their own boards lack women
General counsel for four local public companies signed a letter expressing disappointment in the diversity of law-firm leaders. Those four companies have three female board members, combined.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of JNCE.O earnings conference call or presentation 13-Nov-18 1:00pm GMT
Q3 2018 Jounce Therapeutics Inc Earnings Call
- GlobeNewswire•4 months ago
Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014
CAMBRIDGE, Mass., Jan. 03, 2019 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies.
- GlobeNewswire•4 months ago
Jounce Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2019 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies.
- Insider Monkey•4 months ago
Hedge Funds Are Crazy About Jounce Therapeutics, Inc. (JNCE)
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article, we look at what those funds think of Jounce Therapeutics, Inc. (NASDAQ:JNCE) based on that […]
- GlobeNewswire•5 months ago
Report: Exploring Fundamental Drivers Behind Matrix Service, NantHealth, Earthstone Energy, Jounce Therapeutics, BeiGene, and Oxford Immunotec Global — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•5 months ago
Jounce Therapeutics, Inc. (JNCE) Reports Q3 Loss, Tops Revenue Estimates
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 32.35% and 13.50%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire•5 months ago
Jounce Therapeutics Reports Third Quarter 2018 Financial Results
- Dose escalation cohorts of JTX-2011 Phase 1/2 ICONIC trial, in combination with ipilimumab and in combination with pembrolizumab, on track - - IND filed and clearance to.
- GlobeNewswire•5 months ago
Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that reverse translational and biomarker data derived from its ICONIC (ICOS AgONist Antibody for Immunotherapy in Cancer Patients) trial of JTX-2011 and preclinical data from the ICOS (Inducible T cell CO-Stimulator) program were presented at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting, being held November 9-11, 2018 in Washington, D.C. “The data presented at SITC’s 33rd Annual Meeting demonstrate the role of JTX-2011 in the emergence and agonism of ICOS hi CD4 T effector cells and provide further evidence in support of the biological and clinical activity of JTX-2011.
- GlobeNewswire•5 months ago
Jounce Therapeutics to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 13, 2018
CAMBRIDGE, Mass., Nov. 06, 2018 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies.
- Zacks•6 months ago
Analysts Estimate Jounce Therapeutics, Inc. (JNCE) to Report a Decline in Earnings: What to Look Out for
Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•6 months ago
Jounce Therapeutics to Present Two Posters from the JTX-2011 Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
CAMBRIDGE, Mass., Nov. 02, 2018 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies.
